Nyrada Receives $1.3m R&D rebate for drug programs
- Nyrada (NYR) receives a $1.3 million research and development rebate
- The rebate relates to expenditure on cholesterol-lowering and brain injury drug development programs
- The company says the projects target markets of significant size and considerable unmet clinical needs
- The amount received will partially fund the progression of two Phase I clinical trials, as well as the working capital requirements of Nyrad a
- The amount received will partially fund the progression of these two Phase I clinical trials, as well as the working capital requirements of Nyrad a
- Shares in Nyrad a were up 4 per cent and last traded at 26 cents each
